Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402018 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL14410734 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL24762766 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| Hydrochloric Acid SCHEMBL30005366 | 0.98 | CHRM2 (0.57) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2267993 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22569401 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL178638 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL21219895 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL23807724 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30853292 | 0.89 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| EP-4587435-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024056077-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-21 | — | — | WO | disclosed |
| EP-4308097-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | The Regents Of The University Of Michigan (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023138362-A1 | WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2022197690-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2847208-B1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8889854-B2 | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130296554-A1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-7547690-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | CHRM2 4788/4885CHRM1 4834/4885CHRM3 4463/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CHRM2 325/4885CHRM1 462/4885CHRM3 575/4885 |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, NR1H4 | CHRM2 4625/4885CHRM1 4591/4885CHRM3 3672/4885 |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | CHRM2 3569/4885CHRM1 4322/4885CHRM3 3878/4885 |
| US-20130296554-A1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CDK17, UGT2B17 | CHRM2 3787/4885CHRM1 2696/4885CHRM3 2847/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CHRM2 325/4885CHRM1 462/4885CHRM3 575/4885 |
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | HDAC6, HHAT, HDAC1 | CHRM2 3705/4885CHRM1 3727/4885CHRM3 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.